Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

BMS747158

Small molecule · developed by Lantheus Medical Imaging

Phase 1 Most advanced trial (none active)
LNTH Developer

What is BMS747158?

BMS747158 is a compound given as a single intravenous bolus in a study of coronary artery disease, here in a radiolabeled form ([3H] BMS747158).

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Cardiovascular
Developer
Lantheus Medical Imaging (LNTH)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

Conditions studied

Coronary Artery Disease

More from Lantheus Medical Imaging

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the LNTH page.

Follow LNTH, the company behind BMS747158

See LNTH's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LNTH catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.